Patents by Inventor Gerard Cauwenbergh

Gerard Cauwenbergh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
    Patent number: 11926828
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 12, 2024
    Assignee: Phio Pharmaceuticals Corp.
    Inventor: Gerard Cauwenbergh
  • METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1
    Publication number: 20210348169
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: January 15, 2021
    Publication date: November 11, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventor: Gerard Cauwenbergh
  • Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
    Patent number: 10900039
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 26, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventor: Gerard Cauwenbergh
  • METHODS FOR TREATING SKIN DISORDERS AND CONDITIONS UTILIZING HAPTENS
    Publication number: 20190029974
    Abstract: The invention pertains to the use of therapeutic approaches to treat various skin disorders and conditions. In particular, the invention pertains to the treatment of cutaneous cancers and cutaneous metastasis of solid tumors, as well as to the removal of tattoos, using a hapten. The invention provides various topical formulations comprising a hapten for treatment of these skin disorders and conditions.
    Type: Application
    Filed: September 9, 2016
    Publication date: January 31, 2019
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Gerard Cauwenbergh, Keith Johnson
  • METHODS FOR THE TREATMENT OF ALOPECIA AREATA UTILIZING GENE MODULATION APPROACHES
    Publication number: 20180263925
    Abstract: The present invention relates to methods and compositions for the treatment of alopecia areata. In some aspects, the present invention relates to haptens for use in treating alopecia areata. In other aspects, the present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds the treatment of alopecia areata. In other aspects, the present invention relates to compositions comprising haptens formulated as gels or ointments.
    Type: Application
    Filed: December 3, 2015
    Publication date: September 20, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Gerard Cauwenbergh, Keith Johnson
  • METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1
    Publication number: 20180030451
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: September 4, 2015
    Publication date: February 1, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventor: Gerard Cauwenbergh
  • METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
    Publication number: 20160304875
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications. Aspects of the invention provide nucleic acid molecules for the prophylactic treatment of wounding to reduce scarring. Herein, it is demonstrated that a specific nucleic acid molecule, RXI-109 (targeting connective tissue growth factor (CTGF)), given prophylactically, reduces scarring during wound healing.
    Type: Application
    Filed: December 4, 2014
    Publication date: October 20, 2016
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Gerard Cauwenbergh, Pamela A. Pavco, Lyn Libertine, Karen G. Bulock, James Cardia